The research collaboration will include ETI-211, an HP antibody for the treatment of MRSA infections.
Under the terms of the agreement Elusys and Pfizer will collaborate on determining the full product profile of ETI-211 and perform research on other indications of the HP antibody technology. Elusys will receive an upfront equity investment, R&D funding plus near-term research milestones.
“In parallel with the collaborative research on ETI-211, Elusys will continue to advance its other internal clinical development programs. These include Anthim, our phase I therapeutic for anthrax infection and our HIV HP antibody and CR1 Vaccine programs,” commented Elizabeth Posillico, president & CEO of Elusys Therapeutics.
HP antibodies represent a unique approach to the treatment of a variety of infectious diseases by enhancing the effectiveness of the body’s natural defense mechanisms to remove and destroy life-threatening pathogens.
In previously reported studies by Elusys, mice given ETI-211 prophylactically were completely protected against MRSA. Further, all ETI-211 treated animals survived a second lethal challenge of either MRSA or S. epidermidis months later, with no additional drug treatment.